annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 52D LPS-activated dendritic cell vaccine in combination with immunomodulatory
dose of cytoxan in patients with stage IV melanoma: Phase I/IIa clinical trial.
(Abstract #TPS313)
A. K. Palucka, H. Ueno, J. W. Fay, J. Banchereau
Brd. 52E An open-label, multicenter, phase III trial of nab-paclitaxel (NP) versus
dacarbazine (DTIC) in previously untreated patients (PTs) with metastatic
malignant melanoma (MMM). (Abstract #TPS314)
E. Hersh, M. Millward, I. Elias, J. Iglesias
Patient and Survivor Care
Brd. 52F Randomized phase II study of gabapentin alone versus gabapentin plus
tramadol for the management of oxaliplatin-induced peripheral neuropathy.
(Abstract #TPS315)
H. Shim, J. Yoon, J. Hwang, W. Bae, S. Cho, I. Chung
Brd. 52G Evaluation of a Web-based cognitive rehabilitation program for cancer
survivors with self-reported cognitive impairment. (Abstract #TPS316)
V. J. Bray, H. M. Dhillon, J. L. Vardy
Brd. 52H ICORG 07–11: A phase II trial evaluating the efficacy of a radiobiological
based re-irradiation strategy for patients with malignant spinal cord
compression. (Abstract #TPS317)
P. G. Thirion, A. Clayton-Lea, M. Parker, J. Coffey, J. G. Armstrong, D. Hollywood,
All Ireland Co-operative Oncology Research Group (ICORG)
Brd. 53A The effect of dexamethasone on symptom burden in patients with advanced
cancer. (Abstract #TPS318)
S. Yennurajalingam, J. L. Palmer, J. M. Reuben, E. Bruera
Brd. 53B A randomized placebo-controlled trial of melatonin for poor appetite in
advanced cancer patients. (Abstract #TPS319)
E. Del Fabbro, S. Dalal, R. Dev, E. Bruera
Brd. 53F A randomized, controlled trial of parenteral hydration in patients with
advanced cancer. (Abstract #TPS320)
E. Bruera, K. O. Anderson, J. L. Palmer, M. Z. Cohen, B. Coldman, L. E. Roberts,
W. L. Shen, M. B. Lake
Brd. 53G A randomized, double-blind, controlled trial of methylphenidate for fatigue in
patients with advanced cancer. (Abstract #TPS321)
E. Bruera, V. Valero, W. Breitbart, Y. Guo, J. L. Palmer, M. Z. Cohen, C. Scott,
M. B. Lake
Brd. 53H Phase II randomized study of compound Chinese herbal extract LC09 for
external treatment of hand-foot syndrome induced by anticancer therapy.
(Abstract #TPS322)
L. Jia
Brd. 54A Feasibility of a comprehensive lifestyle modification program during and for
one year after completing cancer treatment in breast and prostate cancer
patients in a large urban health center. (Abstract #TPS323)
E. M. Walker, D. Kerrigan, S. Keteyian, S. Brown, R. Filipiak, N. Martinez, J. K.
Ehrman
Brd. 54B A randomized comparison of oral methadone as a “first-switch” opioid
versus opioid switching between sustained-release morphine and
oxycodone for oncology outpatients with pain management problems.
(Abstract #TPS324)
A. F. Elsayem, K. T. Bain, J. L. Palmer, J. Bearden, M. Fisch
Brd. 54F Design of an ongoing randomized study on the long-term safety and efficacy
of darbepoetin alfa (DA) administered 500 mcg every three weeks (Q3W) to
non-small cell lung cancer (NSCLC) patients (pts) with anemia concomitant
with chemotherapy (ACC). (Abstract #TPS325)
P. Gascon, D. H. Henry, A. Fleishman, J. E. Borenstein
332